Autolus Therapeutics (AUTL) Free Cash Flow (2017 - 2025)

Autolus Therapeutics (AUTL) has 9 years of Free Cash Flow data on file, last reported at -$66.4 million in Q4 2025.

• Quarterly Free Cash Flow fell 35.46% year-over-year to -$66.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$302.6 million (down 32.52% YoY) and the FY2025 annual result came in at -$302.6 million, down 32.52% from the prior year.
• Free Cash Flow climbed to -$66.4 million in Q4 2025, from -$72.3 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$10.7 million in Q4 2021 to a low of -$86.3 million in Q3 2024.
• A 5-year average of -$46.9 million and a median of -$41.4 million in 2023 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2021 — Free Cash Flow soared 67.64% — and 2024, when it slumped 107.09%.
• Tracing AUTL's Free Cash Flow over 5 years: stood at -$10.7 million in 2021, then tumbled by 41.48% to -$15.2 million in 2022, then plunged by 73.1% to -$26.3 million in 2023, then tumbled by 86.42% to -$49.0 million in 2024, then sank by 35.46% to -$66.4 million in 2025.
• The last three Free Cash Flow figures came in at -$66.4 million (Q4 2025), -$72.3 million (Q3 2025), and -$80.1 million (Q2 2025), per Business Quant data.